Lung Cancer

Lung cancer sits in a strange spot in the VA rating system. The diagnosis itself is almost never the contested question. Either there's a pathology report or there isn't. What gets contested is the path to service connection (which presumptive lane applies, or whether a direct nexus opinion holds up against the smoking history) and what the rating looks like six months after treatment ends.

I pulled the BVA dataset for lung cancer and found 649 cases tagged with lung cancer as the primary issue. The grant rate is 40 percent. That's well above the overall Board average of roughly 33 percent, and the reason is structural: lung cancer has two strong presumptive lanes (Agent Orange for veterans with qualifying herbicide-covered service and the 38 USC §§ 1119 and 1120 toxic-exposure framework) that remove the nexus question for veterans who meet every requirement. Ionizing radiation provides a separate presumption under 38 CFR § 3.309(d) or a development procedure under § 3.311 for a smaller group. When no presumption applies, the claim becomes a fight over whether the evidence connects a non-tobacco in-service exposure to the cancer.

This page walks through the DC 6819 rating mechanics, the exact presumptive and radiation pathways, the tobacco-use bar under 38 USC § 1103, the six-month re-evaluation, and the patterns that separate granted lung cancer claims from denied ones at the Board.

TL;DR

• Lung cancer is rated under 38 CFR § 4.97 Diagnostic Code 6819. The rating is 100 percent during active treatment, with a mandatory VA examination six months after treatment ends, after which the rating drops to whatever the residuals support.
• In my BVA dataset, lung cancer shows up as the primary condition in 649 decisions with a 40 percent grant rate, well above the Board's overall average.
• The Agent Orange presumption under 38 CFR § 3.309(e) covers lung cancer (and respiratory cancers generally) for Vietnam-era veterans with qualifying service. This lane removes the nexus question entirely.
• The broad toxic-exposure presumption comes from 38 USC §§ 1119 and 1120. Section 1120 covers respiratory cancer of any type for a covered veteran. Section 3.320 is a separate, narrower regulation covering nine named rare respiratory-cancer histologies and narrower service criteria.
• The tobacco bar at 38 USC § 1103 prevents direct service connection based on in-service tobacco use, but it does not prohibit a grant under an independently satisfied disease presumption. A smoking history does not by itself erase a valid presumption, which remains subject to the ordinary rebuttal rules.
• The residuals rating after the six-month re-evaluation is where most rating disputes happen. Residuals run from pulmonary function deficits (rated under DC 6600 series) to post-surgical residuals after lobectomy or pneumonectomy (DC 6844) to scarring and fibrosis from radiation.
• The 100 percent active-treatment rating returns automatically on recurrence or metastasis. Veterans whose cancer comes back move from a residuals rating back to 100 percent for the new active-treatment phase.

DC 6819 and the 100 Percent Active-Treatment Rule

Lung cancer is rated under 38 CFR § 4.97, Diagnostic Code 6819, "Neoplasms, malignant, any specified part of respiratory system exclusive of skin growths." The diagnostic code covers cancers of the lung, bronchus, trachea, larynx, pharynx, and pleura.

The full regulatory text is short:

"Neoplasms, malignant, any specified part of respiratory system exclusive of skin growths: 100. NOTE: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals."

This is the same temporal structure used for malignant neoplasms across the rating schedule. It has three moving pieces.

The 100 percent floor during active treatment is automatic. As long as the veteran is undergoing surgical, radiation, chemotherapy, or other antineoplastic treatment for the lung cancer, the rating is 100 percent. There's no severity threshold to clear. Diagnosis plus active treatment plus service connection equals 100 percent.

The six-month re-evaluation is mandatory and falls on VA. The regulation requires VA to schedule a re-examination six months after the last day of active treatment. If VA fails to schedule the examination, the 100 percent rating continues by default. Veterans don't have to chase the re-examination. The burden sits with VA to move the case forward. In practice, the re-exam request usually shows up on its own.

The residuals rating is whatever the predominant residual supports. Most lung cancer treatment leaves measurable residuals: reduced pulmonary function from surgical removal of lung tissue, radiation-induced lung scarring (pulmonary fibrosis), or persistent cough and dyspnea from treatment effects. The residuals rate under whichever diagnostic code captures the dominant impairment. A lobectomy patient with reduced FEV-1 rates under the pulmonary function tables. A radiation patient with interstitial lung disease rates under DC 6825. A veteran with no measurable residuals (rare but possible after early-stage resection) can drop to 0 percent.

The temporal structure has one more feature worth flagging: recurrence resets the clock. If the cancer recurs or metastasizes, the 100 percent rating returns for the new active-treatment phase, and a new six-month re-evaluation runs after that round of treatment ends.

The Agent Orange Presumption Drives Most Vietnam-Era Wins

The Agent Orange presumptive list at 38 CFR § 3.309(e) includes respiratory cancers. The relevant statutory authority is 38 USC § 1116. Lung cancer was added to the presumptive list in 1994 (Department of Veterans Affairs final rule following the National Academy of Sciences review), and it has remained on the list since.

The qualifying service definition has expanded multiple times since the original rule:

• Boots-on-ground Vietnam service was the original qualifying category. Veterans with documented in-country service in Vietnam between January 9, 1962 and May 7, 1975 qualify.
• Blue Water Navy service was added by the Blue Water Navy Vietnam Veterans Act of 2019. Veterans who served in the offshore waters of Vietnam (within 12 nautical miles of the coast) during the same period now qualify under the same framework.
• Thailand Air Force base perimeter service has been recognized through VA policy, covering certain veterans whose duties placed them near the perimeter of specific Royal Thai Air Force bases.
• Korean DMZ service between April 1, 1968 and August 31, 1971 also qualifies.

For any veteran with qualifying service who develops lung cancer, the Agent Orange presumption operates the same way: the nexus is presumed. The veteran does not need a medical opinion connecting the cancer to herbicide exposure. The regulation does the connecting.

This is why the lung cancer grant rate runs above the Board average. A substantial fraction of lung cancer claims at the BVA come from veterans in the Agent Orange qualifying-service window, and for those veterans, the only contested questions are usually whether the qualifying service is adequately documented and whether the cancer fits the regulatory definition.

The qualifying-service question gets litigated more than the cancer question. A Blue Water Navy veteran whose ship's logs are missing or whose deck logs don't clearly place the ship within 12 nautical miles may end up fighting the qualifying-service question for years. A veteran who served in Thailand but whose MOS doesn't obviously fit the Air Force base perimeter framework may need detailed unit records to establish qualification.

Section 1120 Covers Respiratory Cancer of Any Type

The PACT Act created the broad toxic-exposure disease presumption in 38 USC §§ 1119 and 1120. Section 1119 defines covered service and presumed toxic exposure. Section 1120 supplies the disease presumption and lists "respiratory cancer of any type." Section 1119 alone is not the disease authority.

For this statutory lane, § 1119's covered-service locations and dates are:

• Bahrain, Iraq, Kuwait, Oman, Qatar, Saudi Arabia, Somalia, the United Arab Emirates, and the airspace above them on or after August 2, 1990
• Afghanistan, Djibouti, Egypt, Jordan, Lebanon, Syria, Yemen, Uzbekistan, and the airspace above them on or after September 11, 2001

For a covered veteran, § 1120 covers lung cancer regardless of histologic type. Non-small cell lung cancer, small cell lung cancer, adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma all fall within the statute's "respiratory cancer of any type" language.

Section 3.320 should not be used as the authority for that all-histology statement. It is a separate, narrower regulation covering squamous cell carcinoma of the larynx; squamous cell carcinoma, adenocarcinoma, and salivary-gland-type tumors of the trachea; and adenosquamous carcinoma, large-cell carcinoma, salivary-gland-type tumors, sarcomatoid carcinoma, and typical or atypical carcinoid of the lung. It also uses narrower qualifying-service rules: the Southwest Asia theater during the Persian Gulf War, or Afghanistan, Syria, Djibouti, or Uzbekistan on or after September 19, 2001.

The PACT Act framework is significant for the lung cancer claim pipeline because it captures a population of veterans who were previously fighting direct service connection against airborne hazard exposure (burn pits, oil well fires, particulate matter from the desert environment) without a presumption to fall back on. Before 2022, a Gulf War veteran with lung cancer typically had to produce a medical opinion linking the cancer to specific in-service exposures. The opinion fights were ugly, and most of these claims either lost or remanded for further development.

After 2022, the same veteran files under the PACT Act presumption and skips the opinion fight entirely. The lung cancer claim docket from 2022 forward looks structurally different from the pre-PACT Act docket for this reason.

The Smoking Confounder and 38 USC § 1103

The single most common reason a direct-service-connection lung cancer claim gets denied is smoking. The medical literature is unambiguous that tobacco use is the leading risk factor for lung cancer. C&P examiners and Board members both know this. So when a veteran files a direct claim for lung cancer based on in-service exposures (asbestos, diesel exhaust, industrial chemicals), the smoking history usually shows up as the dominant alternative explanation.

The legal framework governing tobacco-use claims is 38 USC § 1103. The statute reads:

"A veteran's disability or death shall not be considered to have resulted from personal injury suffered or disease contracted in the line of duty in the active military, naval, or air service for purposes of this title on the basis that it resulted from injury or disease attributable to the use of tobacco products by the veteran during the veteran's service."

Translated: VA cannot grant service connection for a disability that is "attributable to the use of tobacco products" during military service. A veteran cannot win a lung cancer claim on the theory that "I started smoking in the Army and that smoking caused my cancer."

This bar applies only to claims granted on a direct basis where the chain of causation runs through in-service tobacco use. It does not apply to:

• Presumptive claims. Section 1103 does not bar a claim that independently satisfies the Agent Orange, §§ 1119 and 1120, or ionizing-radiation presumption. A smoking history does not automatically defeat those lanes, although the ordinary statutory and regulatory rebuttal rules still apply.
• Direct claims based on non-tobacco in-service exposures. A veteran who can show direct exposure to asbestos, radioactive material, or other carcinogenic substances during service can win on a direct theory, with a medical opinion attributing the cancer to that exposure rather than to tobacco use.

The practical effect is that most contested lung cancer claims at the Board fall into one of three patterns:

1. The presumptive claim: The veteran satisfies the service and disease requirements for Agent Orange, §§ 1119 and 1120, or ionizing radiation. Section 1103 does not itself bar the presumption.

1. The direct claim with strong non-tobacco evidence: The veteran has documented in-service exposure to a known carcinogen (asbestos in shipboard environments, ionizing radiation from atomic testing, specific industrial chemicals) and a medical opinion explicitly attributing the cancer to that exposure rather than to tobacco use. These claims can win when the opinion is strong, but they're the minority of granted lung cancer claims.

1. The direct claim that hangs on tobacco: The veteran started smoking in service and the entire causation theory runs through that. These claims lose under § 1103. They're the largest single category of denied direct-claim lung cancer cases.

When I read through the patterns, the takeaway is that the Agent Orange and PACT Act lanes do most of the work. Direct claims based on non-tobacco exposures are winnable but require evidence development that most veterans don't have or don't pursue. Direct claims based on smoking lose.

Ionizing Radiation as the Third Presumptive Lane

The third presumptive lane for lung cancer is ionizing radiation. The relevant regulations are 38 CFR § 3.309(d) (radiation-exposed veterans) and 38 CFR § 3.311 (radiogenic diseases).

There are two distinct frameworks here, and they cover different populations.

38 CFR § 3.309(d), radiation-exposed veterans. This regulation provides automatic presumptive service connection for a defined list of cancers for veterans who participated in "radiation-risk activities." The covered activities include atmospheric nuclear weapons testing, post-Hiroshima/Nagasaki occupation, internment as a POW in Japan, and service at specific gaseous diffusion plants (Paducah, Portsmouth, Oak Ridge K-25). Lung cancer is on the presumptive list for radiation-exposed veterans under this regulation. The presumption operates the same way as Agent Orange: qualifying service plus the listed cancer equals presumed service connection.

38 CFR § 3.311, radiogenic diseases. This is a more procedural framework for veterans with documented exposure to ionizing radiation during service who don't fit the § 3.309(d) categories. The regulation requires VA to develop the case by obtaining a radiation dose estimate from the Defense Threat Reduction Agency, then forwarding the case to VA's Under Secretary for Benefits for review. The Under Secretary considers whether the cancer is "at least as likely as not" related to the exposure based on the dose estimate and the latency period. This is a case-by-case adjudication, not a true presumption, but it provides a procedural pathway for veterans with documented radiation exposure that doesn't fit § 3.309(d).

Lung cancer is explicitly listed as a radiogenic disease under § 3.311(b)(2). For veterans with documented in-service radiation exposure that doesn't qualify for the § 3.309(d) presumption, the § 3.311 procedure is the right framework.

The radiation lanes cover a much smaller population than Agent Orange or PACT Act. Most lung cancer claims granted on a presumptive basis run through one of the chemical exposure lanes, not the radiation lane. But for the veterans who fit it, the radiation pathway is real and worth pursuing.

The Six-Month Re-Evaluation and Residuals Rating

The 100 percent active-treatment rating under DC 6819 ends six months after the last day of active treatment, subject to the mandatory VA re-examination. What happens at that re-examination determines the residuals rating going forward.

The residuals are rated under whichever diagnostic code captures the predominant impairment. The most common patterns:

Pulmonary function deficits after lobectomy or pneumonectomy. Surgical removal of lung tissue reduces the volume of lung available for gas exchange. The residual impairment is measured by pulmonary function testing (PFT), with FEV-1, FVC, and DLCO values mapping to the rating tiers in DC 6840 through DC 6845 (the general respiratory PFT framework). Post-surgical residuals after lobectomy or pneumonectomy are rated under DC 6844, which directs the rater to the PFT-based tables. A pneumonectomy patient with severe restrictive impairment often rates at 60 percent or higher. A lobectomy patient with modest residual deficit may rate at 10 to 30 percent.

Radiation pneumonitis and pulmonary fibrosis. Radiation therapy to the chest can cause scarring of lung tissue (radiation pneumonitis acutely, pulmonary fibrosis chronically). The residual rates under DC 6825 (interstitial lung disease) using PFT criteria similar to the post-surgical framework. The fibrosis can progress over time, and re-evaluations after the initial six-month re-exam may capture worsening that supports an increased rating.

Persistent cough, dyspnea, and reduced exercise tolerance. Some veterans have functional symptoms after treatment that don't show up dramatically on PFT but produce real limitation in daily activities. The rating in these cases tends to land in the lower tiers (10 to 30 percent) and may require documentation of symptom severity beyond what PFT alone captures.

Recurrence or metastasis. If the cancer recurs or metastasizes, the 100 percent active-treatment rating returns automatically for the new treatment phase. A patient who completes treatment, drops to a residuals rating at month six, and then has a recurrence at month eighteen would move back to 100 percent for the duration of the new active treatment.

The rating disputes at the Board after the six-month re-evaluation tend to follow the pattern I've seen across other cancer claims: the dispute is rarely about whether the residuals exist, it's about whether they meet the threshold for the next-higher tier under the applicable PFT framework. A veteran with FEV-1 of 65 percent predicted sits at 30 percent under DC 6840 series. A veteran with FEV-1 of 50 percent predicted sits at 60 percent. The gap between those tiers turns on a single PFT number, and PFT numbers can move from exam to exam.

When the rating dispute is about residuals, the path to a higher tier usually involves:

• A current PFT with technically valid spirometry (proper technique, three reproducible efforts, post-bronchodilator values)
• A C&P examination that explicitly addresses the predominant residual and applies the right diagnostic code (DC 6844 for post-surgical residuals, DC 6825 for interstitial lung disease, etc.)
• Documentation of any constitutional or functional symptoms that aren't fully captured by PFT alone

What Wins Lung Cancer Claims at the Board

A few patterns I see consistently in granted lung cancer cases at the BVA.

Qualifying service for a presumptive lane, well-documented. DD-214 and unit records that clearly establish herbicide-covered service, service covered by § 1119, or qualifying radiation-risk activity. The documentation question is usually the contested one for presumptive claims, not the cancer question.

Pathology confirmation of malignancy. A biopsy report or surgical pathology report confirming the malignant diagnosis is essentially required. CT or imaging findings alone are not enough. The malignancy needs to be tissue-confirmed for the DC 6819 rating to apply.

A clear treatment timeline. The 100 percent active-treatment rating depends on documentation that treatment is ongoing or has ended. Surgical records, radiation oncology notes, chemotherapy administration records, and immunotherapy infusion records all qualify. The end-of-treatment date is the start of the six-month clock for the re-evaluation.

For direct claims, a medical opinion that explicitly addresses the non-tobacco exposure pathway. When the presumptive lanes don't apply and the claim depends on direct service connection, the medical opinion has to engage with the specific in-service exposure (asbestos, ionizing radiation, specific carcinogens) and explain why that exposure is the more likely cause than tobacco use. Generic opinions that just say "as likely as not related to service" don't survive the § 1103 framework when the file shows a significant smoking history.

A C&P examination at the six-month mark that engages with the right diagnostic code. Residuals examinations that produce specific PFT values, identify the predominant residual, and apply the correct DC tend to support defensible residuals ratings. Generic exams that just describe the cancer history without addressing current impairment tend to produce low ratings that get appealed.

Bottom Line

Lung cancer is rated under 38 CFR § 4.97 Diagnostic Code 6819. The rating starts at 100 percent during active treatment and continues for six months after treatment ends, after which a mandatory VA re-examination establishes the residuals rating. In my BVA dataset of 649 cases, the grant rate is 40 percent, well above the Board average. The principal presumptive lanes are Agent Orange under 38 CFR § 3.309(e), respiratory cancer of any type under 38 USC §§ 1119 and 1120, and ionizing radiation under 38 CFR § 3.309(d); § 3.311 supplies a case-development procedure rather than an automatic presumption. Section 3.320 is a narrower alternative for nine named rare respiratory cancers and should not be cited as the all-histology authority. The tobacco bar at 38 USC § 1103 prevents direct claims based on in-service smoking, but it does not itself block an independently satisfied presumption. The residuals rating after the six-month re-evaluation depends on what's left after treatment: pulmonary function deficits from lung tissue removal, fibrosis from radiation, or persistent functional symptoms. Recurrence resets the rating to 100 percent for the new active-treatment phase.

Methodology and Limitations

• Data source: 38 CFR § 4.97 DC 6819 (malignant respiratory neoplasms), 38 CFR § 4.97 DC 6840 to 6845 (residuals frameworks), 38 CFR § 3.309(d) and § 3.311 (ionizing radiation), 38 CFR § 3.309(e) and 38 USC § 1116 (Agent Orange), 38 USC §§ 1119 and 1120 (broad toxic-exposure respiratory-cancer presumption), 38 CFR § 3.320 (narrower particulate-matter disease list), 38 USC § 1103 (tobacco-use bar), and Claim Raven's analysis of BVA decisions tagged with lung cancer as the primary condition.
• Sample size: 649 BVA decisions involving lung cancer as the primary condition, with a 40 percent grant rate. Subcategory breakdowns (connection-type splits, denial-reason splits, residuals-rating distributions) are summarized in directional terms rather than precise counts because the underlying classifications continue to be refined as the dataset is reprocessed.
• Limitations: The dataset captures BVA-level decisions. Lung cancer claims granted at the regional office without appeal are not in the sample, and those claims are likely structurally easier (presumptive lane applies, qualifying service obvious) than the appealed claims that reach the Board. The presumptive frameworks have changed multiple times since the original 1994 Agent Orange rule, and older BVA decisions may reflect earlier versions of the qualifying-service definitions. The PACT Act framework is relatively new (2022) and the docket of PACT Act burn-pit lung cancer claims is still maturing at the Board level. These observations describe BVA patterns and are not predictions of individual outcomes. Claim Raven is data analysis, not legal, medical, or VA-accredited advice. If you need help with a lung cancer claim, work with an accredited representative.